Shares of Enanta Pharmaceuticals (ENTA) are down by over 55% in the past month, trading at around $8.
This clinical-stage biotechnology company focused on developing drugs for virology and immunology indications has a clinical trial to watch next month (December).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com